Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1Diabetes Mellitus, Type 2 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 454Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × Dipeptidyl-Peptidase IV Inhibitors × Clear all
NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

Completed
344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

NCT02022007 2017-06-28

BMS-AZPCOS

Woman's

Phase 3 Completed
38 enrolled 17 charts

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡